RESEARCH REPORT
AbbVie Inc.
ABBV
$291.31
As of 2026-11-08
Research note — 2026-11-08. Educational analysis, not financial advice.
The one-line version
AbbVie Inc. trades near $291.31 on a trailing multiple of about 50.1x versus its own 5-year median near 38.1x, against contested Street targets and the usual concentration and execution risks. That's the tension. Everything below is the detail.
That's the tension. Everything below is the detail.
1. What you're paying
| Now | Its own 5-year median | Gap | |
|---|---|---|---|
| P/E (trailing) | ~50.1 | ~38.1 | +31% |
| P/E (forward) | ~18.0 | — | — |
| EPS (TTM) | 5.82 | — | — |
| Gross margin | 73.7% | — | — |
What that means in plain terms: the gap versus the company's own history is the growth or durability the market is already pricing. It is not automatically wrong — it is the bet.
Fair-value anchors on file:
- 5-year median P/E multiple: $221.85 — Applies the 5-year median multiple (38.1x) to trailing EPS.
- Street mean target: $310.65 — Average published analyst target.
- Street target midpoint: $293.50 — Midpoint of $237.00–$350.00 published range.
Street targets run from $237.00 to $350.00. A wide spread means the name is contested, not consensus.
2. What the bulls are counting on
- How Much Do You Need in a Roth IRA at 58 to Replace a $120,000 Salary Tax-Free?
- What Could Stall AbbVie Stock's Run?
- What If You Add Gold And Cash To A Dividend Portfolio?
Sign up free to read the full analysis
Bull case, bear case, assumptions, and what to watch next.
3. What the bears see
- Why Is AbbVie (ABBV) Spending $1.37 Billion On Pipeline And UK Research?
- Pfizer vs. AbbVie: Higher Yield and Cheaper Valuation Give One the Clear Edge
- AbbVie or Chevron: I Can Only Pick One Dividend Stock for the Next 10 Years. Here’s Mine
Sign up free to read the full analysis
Bull case, bear case, assumptions, and what to watch next.
4. What would have to be true
For the stock to justify ~50.1x rather than its 5-year ~38.1x, roughly all of the following need to neutral:
- Growth or margin durability shows up in the next several reports, not just in narrative.
- Key revenue concentrations survive competitive and regulatory pressure.
- Execution on the current product or services cycle stays on schedule.
- The Street target range compresses as results clarify the contested assumptions.
Ask yourself honestly: how many of those would you bet on individually? Multiply your answers together.
Sign up free to read the full analysis
Bull case, bear case, assumptions, and what to watch next.
5. What to watch next
- Next earnings date: 2027-02-02
- Trailing and forward multiples versus the company's own history
- Segment growth rates in the next 10-Q / earnings release
- Material Form 4 and 13F changes
- Whether the Street high-to-low target spread narrows or widens
Sign up free to read the full analysis
Bull case, bear case, assumptions, and what to watch next.
6. What this note does not do
It doesn't tell you to buy or sell. It won't, ever.
You have the valuation in context, the strongest version of both cases, and the specific assumptions the current price depends on. What you do with that depends on your time horizon, your existing exposure, your risk tolerance, and what else you could do with the money — none of which we know.
If you want someone to tell you what to do, you want a licensed financial adviser, and that is a genuinely reasonable thing to want.
Educational and informational purposes only. Not investment advice and not a recommendation to buy or sell any security. GetStockReport is not a registered investment adviser. Figures are as of 2026-11-08 and go stale quickly — verify against primary sources before acting. All investments carry risk including loss of principal. Past performance does not guarantee future results.
8. Analyst ratings & targets
No recent activity
Analyst opinions change frequently. Past upgrades do not predict future returns.
9. Important news
Nov 11, 2026|Want a Dividend Check Every Month? This Dividend ETF Paid You 12 Times in the Past Year(Yahoo)
A deposit lands every month, but the amounts swing by nearly four times from the smallest check to the largest. Before you build a retirement budget around this fund, see what drives the swings and who should skip it.
Nov 11, 2026|Can You Make Money Off Halozyme Stock Now?(Yahoo)
For questions about this article or underlying research, email help@trefis.com.
Nov 11, 2026|Johnson & Johnson vs. Eli Lilly: Which Healthcare Giant's Stock Is a Better Buy for 2027?(Yahoo)
Eli Lilly's sales jumped 44.7% last year, while Johnson & Johnson's steadier profile raises a different question for cautious portfolios.
Nov 11, 2026|Top Analyst Reports for NVIDIA, Walmart & AbbVie(Yahoo)
Today's Research Daily features new research reports on 16 major stocks, including NVIDIA Corp. (NVDA), Walmart Inc. (WMT), AbbVie Inc. (ABBV) as well as two micro-cap stocks, Pioneer Bancorp, Inc. (PBFS) and Aspira Women's Health Inc. (AWHL).
Nov 11, 2026|ABBV Stock Rises More Than 4% in a Month: Time to Buy, Hold or Sell?(Yahoo)
AbbVie's strong immunology and neuroscience growth offset Humira erosion and persistent aesthetics and oncology challenges.
News headlines are reported as-is. Verify important claims with original sources.
10. Insider Form 4 activity
No recent activity
Form 4 filings are routine transactions. Scheduled sales (10b5-1 plans) are normal and not signals.
11. Institutional 13F holdings
| Fund | Shares | Position | Change |
|---|---|---|---|
| Vanguard Group | 162,578,655 | $37.1B | — |
| State Street | 82,596,748 | $20.8B | — |
| BlackRock | 51,154,925 | $8.8B | — |
| BlackRock Institutional Trust | 1,547,928 | $96.9M | — |
These are 45-day lagged filings (SEC requirement). Position changes happened in the past.
12. Earnings this week
No recent activity
Earnings dates are estimates and may shift. EPS estimates are consensus, not predictions.